Appendix 5

Reviewer Relationships With Industry and Other Entities—2009 ACCF/AHA Focused Update on Perioperative Beta Blockade

Peer ReviewerRepresentationConsultantSpeakerOwnership/Partnership/PrincipalResearchInstitutional, Organizational, or Other Financial BenefitExpert Witness
Dr. Jeffrey Cavendish• Official Reviewer—ACCF Board of GovernorsNone
  • Novartis

  • Bristol-Myers Squibb/Sanofi-aventis

  • Pfizer

NoneNoneNoneNone
Dr. Jerold Levy• Official Reviewer—American Heart Association
  • Baxter

  • Cubist

  • Dyax

  • Novo Nordisk

  • The Medicines Co.

  • Organon

  • GlaxoSmithKline

  • The Medicines Co.

None• Eli LillyNoneNone
Dr. Robert A. Guyton• Official Reviewer—ACCF/AHA Task Force on Practice Guidelines• MedtronicNoneNoneNoneNoneNone
Dr. Rick Nishimura• Official Reviewer—ACCF Board of TrusteesNoneNoneNoneNoneNoneNone
Dr. Thomas Ryan• Official Reviewer—American Heart Association• PhillipsNoneNoneNoneNoneNone
Dr. Herbert Aronow• Organizational Reviewer—Society for Vascular Medicine• Pfizer
  • Pfizer

  • Sanofi-aventis

NoneNoneNoneNone
Dr. Mina K. Chung• Organizational Reviewer—Heart Rhythm SocietyNoneNoneNoneNoneNoneNone
Dr. Mylan Cohen• Organizational Reviewer—American Society of Nuclear Cardiology• Astellas• AstellasNoneNoneNoneNone
Dr. John Ellis• Organizational Reviewer—Society of Cardiovascular Anesthesiologists• Baxter
  • Baxter

  • The Medicines Co.

NoneNoneNoneNone
Dr. Robert Hamilton• Organizational Reviewer—Heart Rhythm SocietyNoneNoneNoneNoneNoneNone
Dr. Thomas Holly• Organizational Reviewer—American Society of Nuclear CardiologyNone• AstellasNone• AstellasNoneNone
Dr. Clifford Kavinsky• Organizational Reviewer—Society for Cardiovascular Angiography and Interventions• Possis CorpNoneNone• Possis CorpNoneNone
Dr. Martin G. Keane• Organizational Reviewer—American Society of Echocardiography• PfizerNoneNone• Edwards ScientificNone• Petroff & Associates, plaintiff
Dr. Lois Killewich• Organizational Reviewer—Society for Vascular SurgeryNoneNoneNoneNoneNoneNone
Dr. Smadar Kort• Organizational Reviewer—American Society of EchocardiographyNoneNoneNoneNoneNoneNone
Dr. Martin London• Organizational Reviewer—Society of Cardiovascular AnesthesiologistsNoneNoneNoneNoneNoneNone
Dr. Sriharis Naidu• Organizational Reviewer—Society for Cardiovascular Angiography and InterventionsNoneNoneNoneNoneNoneNone
Dr. Todd Rasmussen• Organizational Reviewer—Society for Vascular SurgeryNone• Bristol-Myers SquibbNoneNoneNoneNone
Dr. Yung Wei-Chi• Organizational Reviewer—Society for Vascular MedicineNoneNone• PfizerNoneNoneNone
Dr. Theodore A. Bass• Content Reviewer—ACCF Interventional CouncilNoneNoneNoneNoneNoneNone
Dr. Mark A. Creager• Content Reviewer—ACCF/AHA Task Force on Practice Guidelines
  • BioMarin

  • Genzyme

  • Sanofi-aventis

  • Sigma Tau

  • Vascutek

NoneNone
  • Merck

  • Sanofi-aventis

NoneNone
Dr. Kim Eagle• Content Reviewer
  • NHLBI

  • Sanofi-aventis

NoneNone
  • Gore

  • Sanofi-aventis

None• Defense witness, Yasbeck v. Providence St. Joseph Medical Center, et al.
Dr. Gabriel Gregoratos• Content ReviewerNoneNoneNoneNoneNoneNone
Dr. David L. Holmes• Content Reviewer—ACCF Interventional CouncilNoneNoneNoneNoneNoneNone
Dr. Harlan M. Krumholz• Content Reviewer—ACCF/AHA Task Force on Practice Guidelines
  • AHA

  • Centegen/Life Tech

NoneNone
  • ACC-NCDR ICD Registry

  • Colorado Foundation for Medical Care

  • Amgen

  • Massachusetts Medical Society

  • UnitedHealth

  • Voluntary Hospitals of America

None
Dr. Frederick G. Kushner• Content Reviewer—ACCF/AHA Task Force on Practice GuidelinesNoneNoneNone
  • AstraZeneca

  • Atherogenics

  • Novartis

  • Pfizer

NoneNone
Dr. Debrata Mukherjee• Content Reviewer—ACCF Cardiac Catheterization CommitteeNoneNoneNoneNoneNoneNone
Dr. Richard L. Page• Content Reviewer—ACCF/AHA Task Force on Practice GuidelinesNoneNoneNoneNoneNoneNone
Dr. Christopher L. White• Content Reviewer—ACCF Interventional Council• BaxterNoneNone• Boston ScientificNoneNone

This table represents the relevant relationships with industry and other entities that were disclosed at the time of peer review. It does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% or more of the voting stock or share of the business entity or ownership of $10 000 or more of the fair market value of the business entity, or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review.

ACC indicates American College of Cardiology; ACCF, American College of Cardiology Foundation; AHA, American Heart Association; NCDR ICD Registry, National Cardiovascular Data Registry for implantable cardioverter defibrillators; and NHLBI, National Heart, Lung, and Blood Institute.

  • Significant (>$10 000) relationship.